triple-negative-breast-cancer

Documents about triple-negative-breast-cancer

• A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)#890791ClinicalTrials.gov
• A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)#807577ClinicalTrials.gov
• Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer#471442ClinicalTrials.gov
• Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT#1007710ClinicalTrials.gov
• A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).#871657ClinicalTrials.gov
• Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial#978844ClinicalTrials.gov
• Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer#274674IRIS
• A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies#871908ClinicalTrials.gov
• A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.#1030072ClinicalTrials.gov
• A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin#886911ClinicalTrials.gov
• Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer#884426ClinicalTrials.gov
• Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC#230401ClinicalTrials.gov
• Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)#980796ClinicalTrials.gov
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)#841847ClinicalTrials.gov
• Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer#307306ClinicalTrials.gov
• Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer#888078ClinicalTrials.gov
• Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy#828315ClinicalTrials.gov
• Axillary Nodal Burden in HER2+ and TNBC#846194ClinicalTrials.gov
• A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers#838092ClinicalTrials.gov
• Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors#883589ClinicalTrials.gov
• Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer#896906ClinicalTrials.gov
• Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment#883791ClinicalTrials.gov
• A Study of PY314 in Subjects With Advanced Solid Tumors#905310ClinicalTrials.gov
• Organoids From Breast Cancer Patients Treated With Neoadjuvant Therapy#836583ClinicalTrials.gov
• Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients#967521ClinicalTrials.gov
• Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer#909205ClinicalTrials.gov
• Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)#152429ClinicalTrials.gov
• Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial#250324HAL (France)
• Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer#875157ClinicalTrials.gov
• Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy#855254ClinicalTrials.gov
• Modulation of the response to immunotherapy in triple-negative breast cancer: the role of the microbiota and microbial metabolites in the tumor microenvironment#642682Europe PMC
• Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel#912804ClinicalTrials.gov
• Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer#869235ClinicalTrials.gov
• Homologous recombination pathway alterations in basal-like breast cancer#418000HAL (France)
• QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer#847524ClinicalTrials.gov
• TIP in Patients Affected by Metastatic TNBC#356460ClinicalTrials.gov
• Olinvacimab With Pembrolizumab in Patients With mTNBC#847330ClinicalTrials.gov
• Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer#881241ClinicalTrials.gov
• Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)#841150ClinicalTrials.gov
• Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer#882416ClinicalTrials.gov
• A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer#910019ClinicalTrials.gov
• Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy#1010240ClinicalTrials.gov
• A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients#805598ClinicalTrials.gov
• Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer#893611ClinicalTrials.gov
• ARGONAUT: Stool and Blood Sample Bank for Cancer Patients#121332ClinicalTrials.gov
• Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy#863935ClinicalTrials.gov
• A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)#849721ClinicalTrials.gov
• Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer#366590ClinicalTrials.gov
• Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer#843342ClinicalTrials.gov
• Clinical, pathological, treatment, and follow-up data of patients with triple-negative breast cancer treated with carboplatin-containing neoadjuvant chemotherapy#443363Repositório de Dados de Pesquisa da Unicamp Dataverse OAI Archive